Avsar.

Healthcare · Pharmaceuticals

Procter & Gamble Health Ltd (PGHL)

₹5,603.00

Mkt cap
₹9,407 Cr
P/E ratio
28.20
P/B
17.73
Div yield
2.74%
ROE
61.90%
ROCE
83.90%
EPS (TTM)
₹198.69
Book value
₹316
52W range
4,779–6,919
Sector
Healthcare

Price history

Previous close

P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. [1]

NSE PGHLBSE 500126
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsNeutral
52-week range
−19.01% from high
₹5,603
₹4,779+17.25% from low₹6,919
Current
₹5,603.00
Prev close
₹5,683.00
Day
−1.41%
Price performance
1D
−1.41%
1W
−3.00%
1M
−6.08%
3M
−10.14%
6M
+14.95%
1Y
−11.51%
YTD
−1.73%

Financials

Revenue, profit & margin
P/E ratio
28.2×
PGHL is 20% below the sector median of 35.1×
PGHL28.2×
Sector median35.1×
 Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales301305310252284313310311339325374370364
Expenses256216208185236199186230248205263235264
Operating Profit458910267481141238190120110136100
OPM %15%29%33%27%17%36%40%26%27%37%30%37%27%
Other Income5652-18343454436
Interest0000000000000
Depreciation6677766556666
Profit before tax448810063231111227989119109133129
Tax %32%26%28%26%26%26%25%22%25%26%29%29%26%
Net Profit30667247178291616689789596
EPS in Rs17.9639.5043.4228.0510.1149.6054.7636.8639.8753.3446.7456.9957.92
Raw PDF

Earnings

Results dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +1.26% · closed higher next day 0 of last 1
 Q1FY27
Broadcast6 Aug '26
Earnings day+1.26%
+1 day−1.68%
+5 days−2.24%
+15 days−6.55%
+30 days—
FilingXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Jun 2026
51.82%Promoter
Promoters51.82%
FIIs6.33%0.13
DIIs12.44%1.23
Public29.41%1.11
Ownership trend

Peers

8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
SUNPHARMA₹1,895.0035.994,54,6740.84%2,901+5.95%15,300+10.46%20.53%
DIVISLAB₹9,315.0083.002,47,2840.32%902+65.50%3,080+27.80%21.97%
TORNTPHARM₹4,914.0083.771,86,9130.77%566+5.79%4,921+54.85%15.19%
ZYDUSLIFE₹1,156.9023.701,15,4010.09%990−35.09%8,017+21.96%21.14%
CIPLA₹1,395.0031.491,12,6960.93%786−39.19%7,119+2.33%15.49%
LAURUSLABS₹1,876.7092.741,01,4000.11%362+125.49%2,026+29.10%17.76%
LUPIN₹2,105.0016.1796,2540.86%1,417+16.08%8,277+32.04%29.93%
PGHL₹5,667.0028.239,4072.74%96+9.50%364+7.37%83.88%
Median: 159 Co.₹423.0035.072,2820.08%13+29.60%162+18.62%15.04%

Filings

Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2013nse
Concall transcripts7
PPTSep 2026TranscriptJun 2026TranscriptJun 2025PPTJun 2025PPTDec 2023PPTNov 2022PPTMay 2018
Credit ratings5
Rating update 27 Jun 2019icraRating update 25 Apr 2018icraRating update 26 Feb 2018icraRating update 31 Dec 2016icraRating update 22 Sep 2015icra
Announcements5
Re-Appointment Of Mr. S. Madhavan As Independent Director Of The Company. 4 Sep - Shareholders approved Mr. S. Madhavan’s five-year reappointment as Independent Director from November 15, 2026.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 4 SepShareholder Meeting / Postal Ballot-Outcome of AGM 3 Sep59Th Annual General Meeting Of The Company 12 Aug - Annual Report 2025-26 and AGM notice; 59th AGM on September 3, 2026.Business Responsibility and Sustainability Reporting (BRSR) 12 Aug - Filed Business Responsibility & Sustainability Report for FY ended March 31, 2026.